Journal
Alzheimer's Research & Therapy
Publication Date
11-29-2022
Volume
14
Issue
1
First Page
178
Document Type
Open Access Publication
DOI
10.1186/s13195-022-01110-8
Rights and Permissions
Bateman, R.J., Cummings, J., Schobel, S. et al. Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease. Alz Res Therapy 14, 178 (2022). https://doi.org/10.1186/s13195-022-01110-8 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Recommended Citation
Bateman, Randall J; Cummings, Jeffrey; Schobel, Scott; Salloway, Stephen; Vellas, Bruno; Boada, Mercè; Black, Sandra E; Blennow, Kaj; Fontoura, Paulo; Klein, Gregory; Assunção, Sheila Seleri; Smith, Janice; and Doody, Rachelle S, "Gantenerumab: An anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease." Alzheimer's Research & Therapy. 14, 1. 178 (2022).
https://digitalcommons.wustl.edu/oa_4/2260
Department
ICTS (Institute of Clinical and Translational Sciences)
